WPC Banner  
 
Archived Content

Molecular Imaging in Drug Discovery and Development

 

Day 1 | Day 2 
Download World Pharma Congress Final Brochure or Download Molecular Imaging Brochure 

About This Conference:


The Molecular Imaging in Drug Discovery and Development conference is designed to bring together leading molecular imaging experts from industry and academia, as well as scientists who use their services to accelerate pharmaceutical research. The main emphasis will be made on molecular imaging applications/use of imaging biomarkers on various stages of drug discovery and development.


» Recommended Short Courses 

Molecular Imaging in Drug Discovery and Development: Back to Basics 

Patient Derived Cancer Tissue Xenograft Models  


WEDNESDAY, JUNE 6

12:30 pm Registration

 

TECHNOLOGY MATTERS AND BEYOND 

1:00 Chairperson's Opening RemarksPatrick McConville, Ph.D., CSO & COO, Molecular Imaging, Inc. 

1:10 Industrialized Imaging in a Pharmaceutical Environment

Dinko Gonzalez Trotter, Ph.D., Director, Image Analysis and Physiology, Merck

1:40 Pre-Clinical/Clinical Development and Use of Novel PET Tracers for Establishing Target Expression or Target Binding

Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics Precision Medicine, Worldwide Research & Development, Pfizer, Inc.

The chemical properties required for a successful novel PET tracer will be reviewed. Application of novel PET tracers pre-clinically and clinically with a focus on the type of information generated that aids drug decision-making and establishment of proof-of-concept will be discussed. A description of the potential utility of labeled biologics to assess target expression, target binding and patient stratification will be presented.

2:10 Image Analysis Approaches to Quantifying MRI and PET Imaging Data

Matt Silva, Ph.D., Director, Research Imaging Sciences, Amgen

Following the acquisition of pre-clinical imaging data, it is often desired to quantify features or derive kinetic parameters, which require not only an understanding of the image acquisition and the (patho)physiology but also a keen knowledge of mathematical and statistical models. The development and integration of these methods are laborious and, to minimize bottlenecks, image and data management systems should be considered. This talk with address issues of image analysis and workflow with a focus on multi-modal, core imaging laboratories.

2:40 Cerenkov Luminescence Imaging (CLI) and its Utility in the Drug Discovery Process

Robbie Robertson, Scientist I, Biomedical Imaging Group, Millennium: The Takeda Oncology Company

Cerenkov Luminescence Imaging (CLI) is a recently developed imaging technique which blurs the divide between nuclear and optical imaging. Using common radioisotopes, along with modern CCD imaging equipment, it is possible to image radio-labeled compounds without expensive PET equipment. High throughput increases could reach as high as 10 fold compared to current nuclear imaging techniques by using this technique.


3:10 Drug Evaluation through Imaging Biomarkers: A CRO Perspective

Patrick McConville, Ph.D., CSO & COO, Molecular Imaging, Inc

An overview of the use of multiple pre-clinical imaging modalities for drug evaluation through image-based biomarkers will be provided. Imaging biomarker validation and use will be discussed, and examples using probe facilitated imaging will be highlighted.

3:25 Advanced Techniques in Quantitative Whole Body Autoradiography and Cryo-imaging

XenoBiotic LabsStefan Linehan, Manager, Preclinical Services, XenoBiotic Laboratories, Inc.

Quantitative whole body autoradiography (QWBA) is widely used to provide quantitative tissue distribution data of derived radioactivity from a radiolabeled test article as part of a non-clinical ADME program.  Advancements within the field of Cryo-imaging and Quantitative Autoradiography (CIQA) along with 3D modeling techniques provide an innovative approach for observing the site-specific localization of radioactivity and drug-induced or naturally occurring abnormalities.  These advancements in CIQA can be used to provide useful information in the fields of toxicology, pharmacology, oncology (tumor modeling), and neurology.

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

4:10 Imaging in Translational Medicine: The BI Approach

Heiko Niessen, Ph.D., Translational Medicine Expert for Clinical Imaging, Translational Medicine, Boehringer Ingelheim Pharma GmbH & CO. KG

Similar to pre-clinical studies, pharmacodynamic endpoints in exploratory proof-of-concept studies are assessed using biomarkers, including imaging biomarkers. Therefore, translational imaging biomarkers are an important part of the clinical development program to foster and build hypothesis about the mechanism, to test the clinical concept, to differentiate programs with similar clinical outcome, to support go/no-go decisions, and to de-risk large investments.

4:40 Interactive Discussion Groups

Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.

Image Analysis: Problems and SolutionsMatt Silva, Ph.D., Director, Research Imaging Sciences, Amgen 

fMRI for Drug Discovery: Potentials and PitfallsFuqiang Zhao Ph.D., Senior Research Scientist, Imaging, Merck Research Labs 

Imaging for Drug Toxicity ScreeningGuillaume Normand, Investigator II, Novartis Pharmaceuticals Corporation 

Cerenkov Luminescence Imaging: Strengths and LimitationsRobbie Robertson, Scientist I, Biomedical Imaging Group, Millennium: The Takeda Oncology Company 

Scale Up of Translational Preclinical Imaging Biomarker Assays for Decision Making in Drug Discovery and DevelopmentPatrick McConville, Ph.D., CSO & COO, Molecular Imaging, Inc.  

5:40 End of Day


6-9 pm DINNER SHORT COURSE: 

Molecular Imaging in Drug Discovery and Development: Back to Basics *

  • Strength and limitations of various imaging modalities
  • Multimodality imaging
  • Generation of imaging agents for optical, MR, and nuclear imaging
  • Image analysis

Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics Precision Medicine, Worldwide Research & Development, Pfizer, Inc.


* Separate Registration Required.



 

Day 1 | Day 2 
Download World Pharma Congress Final Brochure or Download Molecular Imaging Brochure 

Submit Speaker Proposal 


WPC Agenda Download Icon

Arrow 2014 Final Brochure 


Arrow View All Sponsors

Arrow View All Media Partners 


SPONSORSHIPS & EXHIBITS

The exhibit hall has sold out the past four years, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Joseph Vacca
Associate Director, Business Development
781-972-5431
jvacca@healthtech.com 

 

 

Testimonials

WPC Quotes